Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios

• Auteurs principaux: Komal Akhtar MD (Auteur), Metlapalli Venkata Sravanthi MD (Auteur), Josephine D'Angelo MD (Auteur), Abirami Sivapiragasam MD (Auteur)
• Format: Livre
• Publié: SAGE Publishing, 2022-08-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Cemiplimab, a monoclonal antibody directed against programmed death receptor 1 (PD-1), has shown promising results in cutaneous squamous cell carcinoma (cSCC). In a nonrandomized trial where cemiplimab 3 mg/kg was given every 2 weeks for up to 96 weeks, a 44% response rate was noted. This case serie...